Takeda’s Adcetris (brentuximab vedotin) Receives EC’s Approval for Previously Untreated CD30+ Stage III Hodgkin Lymphoma
Shots:
- The EC has approved Adcetris in combination with doxorubicin, vinblastine, and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma
- The approval was based on the P-III trial (ECHELON-1) evaluating Adcetris (ADC directed at CD30) + AVD vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in adult patients. The trial met its 1EPs of modified PFS, as well as 2EPs of OS & showed a significant improvement in OS in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma
- The safety profile was consistent with prior studies with no new safety signals. Adcetris received marketing authorization from regulatory authorities in 70+ countries for r/r Hodgkin lymphoma and sALCL
Ref: Takeda | Image: Takeda
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
